3bgl: Difference between revisions
No edit summary |
No edit summary |
||
| Line 31: | Line 31: | ||
</div> | </div> | ||
<div class="pdbe-citations 3bgl" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 3bgl" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 42: | Line 39: | ||
[[Category: Park, W K.C]] | [[Category: Park, W K.C]] | ||
[[Category: Pavlovsky, A]] | [[Category: Pavlovsky, A]] | ||
[[Category: Alternative splicing]] | |||
[[Category: Cholesterol biosynthesis]] | [[Category: Cholesterol biosynthesis]] | ||
[[Category: Endoplasmic reticulum]] | [[Category: Endoplasmic reticulum]] | ||
| Line 51: | Line 49: | ||
[[Category: Oxidoreductase]] | [[Category: Oxidoreductase]] | ||
[[Category: Peroxisome]] | [[Category: Peroxisome]] | ||
[[Category: Polymorphism]] | |||
[[Category: Statin]] | [[Category: Statin]] | ||
[[Category: Steroid biosynthesis]] | [[Category: Steroid biosynthesis]] | ||
[[Category: Transmembrane]] | [[Category: Transmembrane]] | ||
Revision as of 11:02, 25 October 2017
Hepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsHepatoselectivity of Statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
Structural highlights
Function[HMDH_HUMAN] Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins. Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMed4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Munchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.,Park WK, Kennedy RM, Larsen SD, Miller S, Roth BD, Song Y, Steinbaugh BA, Sun K, Tait BD, Kowala MC, Trivedi BK, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu GH, Robertson A, Sekerke C Bioorg Med Chem Lett. 2008 Feb 1;18(3):1151-6. Epub 2007 Dec 5. PMID:18155906[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||||